nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Teniposide—lymphatic system cancer	0.196	0.367	CbGbCtD
Vardenafil—CYP3A5—Vincristine—lymphatic system cancer	0.0942	0.176	CbGbCtD
Vardenafil—CYP3A4—Cytarabine—lymphatic system cancer	0.0775	0.145	CbGbCtD
Vardenafil—CYP3A4—Teniposide—lymphatic system cancer	0.0763	0.143	CbGbCtD
Vardenafil—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0534	0.1	CbGbCtD
Vardenafil—CYP3A4—Vincristine—lymphatic system cancer	0.0367	0.0688	CbGbCtD
Vardenafil—Convulsion—Fludarabine—lymphatic system cancer	0.00164	0.00352	CcSEcCtD
Vardenafil—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00163	0.0035	CcSEcCtD
Vardenafil—Arthralgia—Fludarabine—lymphatic system cancer	0.00161	0.00346	CcSEcCtD
Vardenafil—Myalgia—Fludarabine—lymphatic system cancer	0.00161	0.00346	CcSEcCtD
Vardenafil—Haemoglobin—Bleomycin—lymphatic system cancer	0.0016	0.00344	CcSEcCtD
Vardenafil—Haemorrhage—Bleomycin—lymphatic system cancer	0.00159	0.00342	CcSEcCtD
Vardenafil—Discomfort—Fludarabine—lymphatic system cancer	0.00159	0.00341	CcSEcCtD
Vardenafil—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00159	0.0034	CcSEcCtD
Vardenafil—Dyspnoea—Teniposide—lymphatic system cancer	0.00157	0.00336	CcSEcCtD
Vardenafil—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00154	0.00331	CcSEcCtD
Vardenafil—Infection—Fludarabine—lymphatic system cancer	0.00153	0.00329	CcSEcCtD
Vardenafil—Vomiting—Mechlorethamine—lymphatic system cancer	0.00151	0.00325	CcSEcCtD
Vardenafil—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00151	0.00325	CcSEcCtD
Vardenafil—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00151	0.00325	CcSEcCtD
Vardenafil—Rash—Mechlorethamine—lymphatic system cancer	0.0015	0.00322	CcSEcCtD
Vardenafil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0015	0.00322	CcSEcCtD
Vardenafil—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00149	0.0032	CcSEcCtD
Vardenafil—Flushing—Bleomycin—lymphatic system cancer	0.00148	0.00317	CcSEcCtD
Vardenafil—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00146	0.00313	CcSEcCtD
Vardenafil—Myocardial infarction—Vincristine—lymphatic system cancer	0.00145	0.00311	CcSEcCtD
Vardenafil—Feeling abnormal—Teniposide—lymphatic system cancer	0.00145	0.00311	CcSEcCtD
Vardenafil—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00144	0.00308	CcSEcCtD
Vardenafil—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00142	0.00305	CcSEcCtD
Vardenafil—Sweating—Vincristine—lymphatic system cancer	0.00142	0.00304	CcSEcCtD
Vardenafil—Nausea—Mechlorethamine—lymphatic system cancer	0.00142	0.00304	CcSEcCtD
Vardenafil—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00141	0.00303	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00141	0.00302	CcSEcCtD
Vardenafil—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.0014	0.003	CcSEcCtD
Vardenafil—Haemoglobin—Carmustine—lymphatic system cancer	0.0014	0.003	CcSEcCtD
Vardenafil—Haemorrhage—Carmustine—lymphatic system cancer	0.00139	0.00298	CcSEcCtD
Vardenafil—Abdominal pain—Teniposide—lymphatic system cancer	0.00139	0.00298	CcSEcCtD
Vardenafil—Erythema—Bleomycin—lymphatic system cancer	0.00139	0.00298	CcSEcCtD
Vardenafil—Paraesthesia—Fludarabine—lymphatic system cancer	0.00139	0.00297	CcSEcCtD
Vardenafil—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00138	0.00297	CcSEcCtD
Vardenafil—Sweating—Mitoxantrone—lymphatic system cancer	0.00138	0.00296	CcSEcCtD
Vardenafil—Dyspnoea—Fludarabine—lymphatic system cancer	0.00138	0.00295	CcSEcCtD
Vardenafil—Haematuria—Mitoxantrone—lymphatic system cancer	0.00137	0.00295	CcSEcCtD
Vardenafil—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00137	0.00293	CcSEcCtD
Vardenafil—Dyspepsia—Fludarabine—lymphatic system cancer	0.00136	0.00292	CcSEcCtD
Vardenafil—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00136	0.00291	CcSEcCtD
Vardenafil—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00135	0.0029	CcSEcCtD
Vardenafil—Visual impairment—Carmustine—lymphatic system cancer	0.00134	0.00288	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00133	0.00286	CcSEcCtD
Vardenafil—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00132	0.00283	CcSEcCtD
Vardenafil—Pain—Fludarabine—lymphatic system cancer	0.00132	0.00283	CcSEcCtD
Vardenafil—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00131	0.00281	CcSEcCtD
Vardenafil—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0013	0.0028	CcSEcCtD
Vardenafil—Urethral disorder—Vincristine—lymphatic system cancer	0.0013	0.00279	CcSEcCtD
Vardenafil—Eye disorder—Carmustine—lymphatic system cancer	0.0013	0.00279	CcSEcCtD
Vardenafil—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0013	0.00279	CcSEcCtD
Vardenafil—Rhinitis—Mitoxantrone—lymphatic system cancer	0.0013	0.00278	CcSEcCtD
Vardenafil—Hypersensitivity—Teniposide—lymphatic system cancer	0.00129	0.00278	CcSEcCtD
Vardenafil—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00129	0.00277	CcSEcCtD
Vardenafil—Flushing—Carmustine—lymphatic system cancer	0.00129	0.00277	CcSEcCtD
Vardenafil—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00129	0.00276	CcSEcCtD
Vardenafil—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00128	0.00275	CcSEcCtD
Vardenafil—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00127	0.00273	CcSEcCtD
Vardenafil—Asthenia—Teniposide—lymphatic system cancer	0.00126	0.0027	CcSEcCtD
Vardenafil—Malaise—Bleomycin—lymphatic system cancer	0.00125	0.00268	CcSEcCtD
Vardenafil—Pruritus—Teniposide—lymphatic system cancer	0.00124	0.00267	CcSEcCtD
Vardenafil—Cardiac disorder—Vincristine—lymphatic system cancer	0.00123	0.00264	CcSEcCtD
Vardenafil—Mental disorder—Carmustine—lymphatic system cancer	0.00122	0.00261	CcSEcCtD
Vardenafil—Erythema—Carmustine—lymphatic system cancer	0.00121	0.0026	CcSEcCtD
Vardenafil—Angiopathy—Vincristine—lymphatic system cancer	0.0012	0.00258	CcSEcCtD
Vardenafil—Diarrhoea—Teniposide—lymphatic system cancer	0.0012	0.00258	CcSEcCtD
Vardenafil—Mediastinal disorder—Vincristine—lymphatic system cancer	0.0012	0.00257	CcSEcCtD
Vardenafil—Chest pain—Bleomycin—lymphatic system cancer	0.00118	0.00253	CcSEcCtD
Vardenafil—Myalgia—Bleomycin—lymphatic system cancer	0.00118	0.00253	CcSEcCtD
Vardenafil—Back pain—Carmustine—lymphatic system cancer	0.00117	0.00251	CcSEcCtD
Vardenafil—Discomfort—Bleomycin—lymphatic system cancer	0.00117	0.0025	CcSEcCtD
Vardenafil—Mental disorder—Vincristine—lymphatic system cancer	0.00116	0.0025	CcSEcCtD
Vardenafil—Vision blurred—Carmustine—lymphatic system cancer	0.00114	0.00245	CcSEcCtD
Vardenafil—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00114	0.00244	CcSEcCtD
Vardenafil—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00113	0.00243	CcSEcCtD
Vardenafil—Erythema—Mitoxantrone—lymphatic system cancer	0.00113	0.00241	CcSEcCtD
Vardenafil—Infection—Bleomycin—lymphatic system cancer	0.00112	0.00241	CcSEcCtD
Vardenafil—Back pain—Vincristine—lymphatic system cancer	0.00112	0.0024	CcSEcCtD
Vardenafil—Vomiting—Teniposide—lymphatic system cancer	0.00112	0.0024	CcSEcCtD
Vardenafil—Asthenia—Fludarabine—lymphatic system cancer	0.00111	0.00238	CcSEcCtD
Vardenafil—Rash—Teniposide—lymphatic system cancer	0.00111	0.00238	CcSEcCtD
Vardenafil—Dermatitis—Teniposide—lymphatic system cancer	0.00111	0.00237	CcSEcCtD
Vardenafil—Headache—Teniposide—lymphatic system cancer	0.0011	0.00236	CcSEcCtD
Vardenafil—Pruritus—Fludarabine—lymphatic system cancer	0.00109	0.00234	CcSEcCtD
Vardenafil—Back pain—Mitoxantrone—lymphatic system cancer	0.00109	0.00234	CcSEcCtD
Vardenafil—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00106	0.00228	CcSEcCtD
Vardenafil—Hypotension—Bleomycin—lymphatic system cancer	0.00106	0.00227	CcSEcCtD
Vardenafil—Diarrhoea—Fludarabine—lymphatic system cancer	0.00106	0.00227	CcSEcCtD
Vardenafil—Convulsion—Carmustine—lymphatic system cancer	0.00105	0.00225	CcSEcCtD
Vardenafil—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00104	0.00224	CcSEcCtD
Vardenafil—Nausea—Teniposide—lymphatic system cancer	0.00104	0.00224	CcSEcCtD
Vardenafil—Vertigo—Vincristine—lymphatic system cancer	0.00104	0.00223	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00103	0.00221	CcSEcCtD
Vardenafil—Chest pain—Carmustine—lymphatic system cancer	0.00103	0.00221	CcSEcCtD
Vardenafil—Myalgia—Carmustine—lymphatic system cancer	0.00103	0.00221	CcSEcCtD
Vardenafil—Anxiety—Carmustine—lymphatic system cancer	0.00103	0.0022	CcSEcCtD
Vardenafil—Paraesthesia—Bleomycin—lymphatic system cancer	0.00102	0.00218	CcSEcCtD
Vardenafil—Malaise—Mitoxantrone—lymphatic system cancer	0.00101	0.00218	CcSEcCtD
Vardenafil—Dyspnoea—Bleomycin—lymphatic system cancer	0.00101	0.00217	CcSEcCtD
Vardenafil—Convulsion—Vincristine—lymphatic system cancer	0.001	0.00215	CcSEcCtD
Vardenafil—Myalgia—Vincristine—lymphatic system cancer	0.000984	0.00211	CcSEcCtD
Vardenafil—Visual disturbance—Methotrexate—lymphatic system cancer	0.000983	0.00211	CcSEcCtD
Vardenafil—Infection—Carmustine—lymphatic system cancer	0.000982	0.00211	CcSEcCtD
Vardenafil—Vomiting—Fludarabine—lymphatic system cancer	0.000982	0.00211	CcSEcCtD
Vardenafil—Convulsion—Mitoxantrone—lymphatic system cancer	0.000975	0.00209	CcSEcCtD
Vardenafil—Rash—Fludarabine—lymphatic system cancer	0.000973	0.00209	CcSEcCtD
Vardenafil—Dermatitis—Fludarabine—lymphatic system cancer	0.000972	0.00209	CcSEcCtD
Vardenafil—Pain—Bleomycin—lymphatic system cancer	0.000968	0.00208	CcSEcCtD
Vardenafil—Headache—Fludarabine—lymphatic system cancer	0.000967	0.00208	CcSEcCtD
Vardenafil—Tachycardia—Carmustine—lymphatic system cancer	0.000964	0.00207	CcSEcCtD
Vardenafil—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000958	0.00206	CcSEcCtD
Vardenafil—Chest pain—Mitoxantrone—lymphatic system cancer	0.000958	0.00206	CcSEcCtD
Vardenafil—Myalgia—Mitoxantrone—lymphatic system cancer	0.000958	0.00206	CcSEcCtD
Vardenafil—Anxiety—Mitoxantrone—lymphatic system cancer	0.000955	0.00205	CcSEcCtD
Vardenafil—Discomfort—Mitoxantrone—lymphatic system cancer	0.000947	0.00203	CcSEcCtD
Vardenafil—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000943	0.00202	CcSEcCtD
Vardenafil—Infection—Vincristine—lymphatic system cancer	0.000937	0.00201	CcSEcCtD
Vardenafil—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000933	0.002	CcSEcCtD
Vardenafil—Nervous system disorder—Vincristine—lymphatic system cancer	0.000925	0.00198	CcSEcCtD
Vardenafil—Hypotension—Carmustine—lymphatic system cancer	0.000923	0.00198	CcSEcCtD
Vardenafil—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000919	0.00197	CcSEcCtD
Vardenafil—Nausea—Fludarabine—lymphatic system cancer	0.000917	0.00197	CcSEcCtD
Vardenafil—Infection—Mitoxantrone—lymphatic system cancer	0.000913	0.00196	CcSEcCtD
Vardenafil—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000912	0.00196	CcSEcCtD
Vardenafil—Shock—Mitoxantrone—lymphatic system cancer	0.000904	0.00194	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0009	0.00193	CcSEcCtD
Vardenafil—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000896	0.00192	CcSEcCtD
Vardenafil—Insomnia—Carmustine—lymphatic system cancer	0.000894	0.00192	CcSEcCtD
Vardenafil—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000892	0.00191	CcSEcCtD
Vardenafil—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000888	0.00191	CcSEcCtD
Vardenafil—Paraesthesia—Carmustine—lymphatic system cancer	0.000887	0.0019	CcSEcCtD
Vardenafil—Hypotension—Vincristine—lymphatic system cancer	0.000881	0.00189	CcSEcCtD
Vardenafil—Dyspnoea—Carmustine—lymphatic system cancer	0.000881	0.00189	CcSEcCtD
Vardenafil—Somnolence—Carmustine—lymphatic system cancer	0.000878	0.00188	CcSEcCtD
Vardenafil—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00086	0.00184	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000859	0.00184	CcSEcCtD
Vardenafil—Hypotension—Mitoxantrone—lymphatic system cancer	0.000858	0.00184	CcSEcCtD
Vardenafil—Insomnia—Vincristine—lymphatic system cancer	0.000853	0.00183	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000853	0.00183	CcSEcCtD
Vardenafil—Paraesthesia—Vincristine—lymphatic system cancer	0.000847	0.00182	CcSEcCtD
Vardenafil—Pain—Carmustine—lymphatic system cancer	0.000845	0.00181	CcSEcCtD
Vardenafil—Breast disorder—Methotrexate—lymphatic system cancer	0.000841	0.00181	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000837	0.0018	CcSEcCtD
Vardenafil—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000834	0.00179	CcSEcCtD
Vardenafil—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000825	0.00177	CcSEcCtD
Vardenafil—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000819	0.00176	CcSEcCtD
Vardenafil—Somnolence—Mitoxantrone—lymphatic system cancer	0.000817	0.00175	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000814	0.00175	CcSEcCtD
Vardenafil—Feeling abnormal—Carmustine—lymphatic system cancer	0.000814	0.00175	CcSEcCtD
Vardenafil—Asthenia—Bleomycin—lymphatic system cancer	0.000812	0.00174	CcSEcCtD
Vardenafil—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000809	0.00173	CcSEcCtD
Vardenafil—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000808	0.00173	CcSEcCtD
Vardenafil—Pain—Vincristine—lymphatic system cancer	0.000807	0.00173	CcSEcCtD
Vardenafil—Pruritus—Bleomycin—lymphatic system cancer	0.000801	0.00172	CcSEcCtD
Vardenafil—Pain—Mitoxantrone—lymphatic system cancer	0.000785	0.00169	CcSEcCtD
Vardenafil—Abdominal pain—Carmustine—lymphatic system cancer	0.000781	0.00168	CcSEcCtD
Vardenafil—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000771	0.00165	CcSEcCtD
Vardenafil—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000757	0.00162	CcSEcCtD
Vardenafil—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000751	0.00161	CcSEcCtD
Vardenafil—Abdominal pain—Vincristine—lymphatic system cancer	0.000746	0.0016	CcSEcCtD
Vardenafil—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000735	0.00158	CcSEcCtD
Vardenafil—Hypersensitivity—Carmustine—lymphatic system cancer	0.000728	0.00156	CcSEcCtD
Vardenafil—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000726	0.00156	CcSEcCtD
Vardenafil—Vomiting—Bleomycin—lymphatic system cancer	0.00072	0.00154	CcSEcCtD
Vardenafil—Infestation—Methotrexate—lymphatic system cancer	0.000718	0.00154	CcSEcCtD
Vardenafil—Infestation NOS—Methotrexate—lymphatic system cancer	0.000718	0.00154	CcSEcCtD
Vardenafil—Rash—Bleomycin—lymphatic system cancer	0.000714	0.00153	CcSEcCtD
Vardenafil—Dermatitis—Bleomycin—lymphatic system cancer	0.000713	0.00153	CcSEcCtD
Vardenafil—Asthenia—Carmustine—lymphatic system cancer	0.000709	0.00152	CcSEcCtD
Vardenafil—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000697	0.0015	CcSEcCtD
Vardenafil—Hypersensitivity—Vincristine—lymphatic system cancer	0.000695	0.00149	CcSEcCtD
Vardenafil—Sweating—Methotrexate—lymphatic system cancer	0.000688	0.00148	CcSEcCtD
Vardenafil—Haematuria—Methotrexate—lymphatic system cancer	0.000684	0.00147	CcSEcCtD
Vardenafil—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000679	0.00146	CcSEcCtD
Vardenafil—Epistaxis—Methotrexate—lymphatic system cancer	0.000677	0.00145	CcSEcCtD
Vardenafil—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000677	0.00145	CcSEcCtD
Vardenafil—Asthenia—Vincristine—lymphatic system cancer	0.000677	0.00145	CcSEcCtD
Vardenafil—Diarrhoea—Carmustine—lymphatic system cancer	0.000676	0.00145	CcSEcCtD
Vardenafil—Nausea—Bleomycin—lymphatic system cancer	0.000672	0.00144	CcSEcCtD
Vardenafil—Asthenia—Mitoxantrone—lymphatic system cancer	0.000659	0.00141	CcSEcCtD
Vardenafil—Dizziness—Carmustine—lymphatic system cancer	0.000653	0.0014	CcSEcCtD
Vardenafil—Haemoglobin—Methotrexate—lymphatic system cancer	0.000647	0.00139	CcSEcCtD
Vardenafil—Diarrhoea—Vincristine—lymphatic system cancer	0.000645	0.00138	CcSEcCtD
Vardenafil—Haemorrhage—Methotrexate—lymphatic system cancer	0.000644	0.00138	CcSEcCtD
Vardenafil—Pharyngitis—Methotrexate—lymphatic system cancer	0.000639	0.00137	CcSEcCtD
Vardenafil—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000636	0.00136	CcSEcCtD
Vardenafil—Urethral disorder—Methotrexate—lymphatic system cancer	0.000631	0.00135	CcSEcCtD
Vardenafil—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000628	0.00135	CcSEcCtD
Vardenafil—Vomiting—Carmustine—lymphatic system cancer	0.000628	0.00135	CcSEcCtD
Vardenafil—Dizziness—Vincristine—lymphatic system cancer	0.000624	0.00134	CcSEcCtD
Vardenafil—Rash—Carmustine—lymphatic system cancer	0.000623	0.00134	CcSEcCtD
Vardenafil—Dermatitis—Carmustine—lymphatic system cancer	0.000622	0.00134	CcSEcCtD
Vardenafil—Visual impairment—Methotrexate—lymphatic system cancer	0.000621	0.00133	CcSEcCtD
Vardenafil—Headache—Carmustine—lymphatic system cancer	0.000619	0.00133	CcSEcCtD
Vardenafil—Eye disorder—Methotrexate—lymphatic system cancer	0.000602	0.00129	CcSEcCtD
Vardenafil—Tinnitus—Methotrexate—lymphatic system cancer	0.000601	0.00129	CcSEcCtD
Vardenafil—Vomiting—Vincristine—lymphatic system cancer	0.0006	0.00129	CcSEcCtD
Vardenafil—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000598	0.00128	CcSEcCtD
Vardenafil—Rash—Vincristine—lymphatic system cancer	0.000595	0.00128	CcSEcCtD
Vardenafil—Dermatitis—Vincristine—lymphatic system cancer	0.000594	0.00127	CcSEcCtD
Vardenafil—Headache—Vincristine—lymphatic system cancer	0.000591	0.00127	CcSEcCtD
Vardenafil—Nausea—Carmustine—lymphatic system cancer	0.000587	0.00126	CcSEcCtD
Vardenafil—Angiopathy—Methotrexate—lymphatic system cancer	0.000584	0.00125	CcSEcCtD
Vardenafil—Vomiting—Mitoxantrone—lymphatic system cancer	0.000584	0.00125	CcSEcCtD
Vardenafil—Immune system disorder—Methotrexate—lymphatic system cancer	0.000582	0.00125	CcSEcCtD
Vardenafil—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000581	0.00125	CcSEcCtD
Vardenafil—Rash—Mitoxantrone—lymphatic system cancer	0.000579	0.00124	CcSEcCtD
Vardenafil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000579	0.00124	CcSEcCtD
Vardenafil—Headache—Mitoxantrone—lymphatic system cancer	0.000575	0.00123	CcSEcCtD
Vardenafil—Mental disorder—Methotrexate—lymphatic system cancer	0.000564	0.00121	CcSEcCtD
Vardenafil—Erythema—Methotrexate—lymphatic system cancer	0.000561	0.0012	CcSEcCtD
Vardenafil—Nausea—Vincristine—lymphatic system cancer	0.00056	0.0012	CcSEcCtD
Vardenafil—Nausea—Mitoxantrone—lymphatic system cancer	0.000546	0.00117	CcSEcCtD
Vardenafil—Back pain—Methotrexate—lymphatic system cancer	0.000542	0.00116	CcSEcCtD
Vardenafil—Vision blurred—Methotrexate—lymphatic system cancer	0.000528	0.00113	CcSEcCtD
Vardenafil—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00052	0.00112	CcSEcCtD
Vardenafil—Malaise—Methotrexate—lymphatic system cancer	0.000506	0.00108	CcSEcCtD
Vardenafil—Vertigo—Methotrexate—lymphatic system cancer	0.000504	0.00108	CcSEcCtD
Vardenafil—Convulsion—Methotrexate—lymphatic system cancer	0.000486	0.00104	CcSEcCtD
Vardenafil—Arthralgia—Methotrexate—lymphatic system cancer	0.000477	0.00102	CcSEcCtD
Vardenafil—Chest pain—Methotrexate—lymphatic system cancer	0.000477	0.00102	CcSEcCtD
Vardenafil—Myalgia—Methotrexate—lymphatic system cancer	0.000477	0.00102	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000474	0.00102	CcSEcCtD
Vardenafil—Discomfort—Methotrexate—lymphatic system cancer	0.000472	0.00101	CcSEcCtD
Vardenafil—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000458	0.000982	CcSEcCtD
Vardenafil—Infection—Methotrexate—lymphatic system cancer	0.000455	0.000975	CcSEcCtD
Vardenafil—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000449	0.000963	CcSEcCtD
Vardenafil—Skin disorder—Methotrexate—lymphatic system cancer	0.000445	0.000954	CcSEcCtD
Vardenafil—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000442	0.000949	CcSEcCtD
Vardenafil—Hypotension—Methotrexate—lymphatic system cancer	0.000428	0.000918	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000417	0.000895	CcSEcCtD
Vardenafil—Insomnia—Methotrexate—lymphatic system cancer	0.000414	0.000888	CcSEcCtD
Vardenafil—Paraesthesia—Methotrexate—lymphatic system cancer	0.000411	0.000882	CcSEcCtD
Vardenafil—Dyspnoea—Methotrexate—lymphatic system cancer	0.000408	0.000875	CcSEcCtD
Vardenafil—Somnolence—Methotrexate—lymphatic system cancer	0.000407	0.000873	CcSEcCtD
Vardenafil—Dyspepsia—Methotrexate—lymphatic system cancer	0.000403	0.000864	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000395	0.000848	CcSEcCtD
Vardenafil—Pain—Methotrexate—lymphatic system cancer	0.000391	0.00084	CcSEcCtD
Vardenafil—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000377	0.000809	CcSEcCtD
Vardenafil—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000374	0.000803	CcSEcCtD
Vardenafil—Abdominal pain—Methotrexate—lymphatic system cancer	0.000362	0.000776	CcSEcCtD
Vardenafil—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000337	0.000723	CcSEcCtD
Vardenafil—Asthenia—Methotrexate—lymphatic system cancer	0.000328	0.000704	CcSEcCtD
Vardenafil—Pruritus—Methotrexate—lymphatic system cancer	0.000324	0.000695	CcSEcCtD
Vardenafil—Diarrhoea—Methotrexate—lymphatic system cancer	0.000313	0.000672	CcSEcCtD
Vardenafil—Dizziness—Methotrexate—lymphatic system cancer	0.000303	0.000649	CcSEcCtD
Vardenafil—Vomiting—Methotrexate—lymphatic system cancer	0.000291	0.000624	CcSEcCtD
Vardenafil—Rash—Methotrexate—lymphatic system cancer	0.000289	0.000619	CcSEcCtD
Vardenafil—Dermatitis—Methotrexate—lymphatic system cancer	0.000288	0.000619	CcSEcCtD
Vardenafil—Headache—Methotrexate—lymphatic system cancer	0.000287	0.000615	CcSEcCtD
Vardenafil—Nausea—Methotrexate—lymphatic system cancer	0.000272	0.000583	CcSEcCtD
